Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Jean-Denis Docquier manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, DICKENS, AMELIA NICOLE, who is the busiest examiner for the portfolio with 1 pending action. The current pending inventory is located within 1 distinct art unit. This indicates that the prosecution of the biotechnology interests is currently dependent on the review of the assigned examiner and the standards of the art unit.
For the practitioner, this means the current prosecution strategy is tied to the specific requirements and examination culture of 1 distinct art unit and DICKENS, AMELIA NICOLE. Because there are no other examiners or art units involved in the 1 pending office action, the prosecution outcomes are dependent on this point of contact. Practitioners should focus on the specific historical tendencies of the examiner to optimize their approach for the pending inventory in the Biotechnology & Pharmaceuticals area.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DICKENS, AMELIA NICOLE | 1 | 47.2% | +21.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18690387 | AN ENGINEERED YEAST CELL FOR THE DELIVERY OF ANTIBIOTIC-INACTIVATING ENZYMES | DICKENS, AMELIA NICOLE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18690387 | AN ENGINEERED YEAST CELL FOR THE DELIVERY OF ANTIBIOTIC-INACTIVATING ENZYMES | DICKENS, AMELIA NICOLE | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18690387 | AN ENGINEERED YEAST CELL FOR THE DELIVERY OF ANTIBIOTIC-INACTIVATING ENZYMES | DICKENS, AMELIA NICOLE | 1645 | §102§103§112 | Non-Final OA | — | Pending | Mar 08, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialJean-Denis Docquier has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Amelia Nicole Dickens has the most, with 1 of Jean-Denis Docquier's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
